SCHEMBL16619626

SCHEMBL16619626

NCCc1csc(-c2ccccc2Cl)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.69
ALDH1A1 P00352 4/20 0.69
TDP1 Q9NUW8 1/20 0.69
MAOB P27338 2/20 0.46
TAAR1 Q96RJ0 2/20 0.46
CYP19A1 P11511 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HTR2C P28335 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.41
ADORA1 P30542 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619009 0.87 ALDH1A1 (0.73) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL18015816 0.84 L3MBTL1 (0.69) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL2431805 0.81 ALDH1A1 (1.00) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL18014691 0.80 L3MBTL1 (0.63) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL18015824 0.80 ALDH1A1 (0.73) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL5895082 0.80 ALDH1A1 (0.73) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
SCHEMBL14736420 0.78 LMNA (0.56) TAAR1NPC1LMNAMAPTHPGD
SCHEMBL5930632 0.77 ALDH1A1 (0.69) L3MBTL1ALDH1A1TDP1CYP19A1NPC1
Hydrochloric Acid SCHEMBL17261485 0.77 LMNA (0.55) TAAR1NPC1LMNAMAPTHPGD
Hydrochloric Acid SCHEMBL17261571 0.77 LMNA (0.55) TAAR1NPC1LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052495-B1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2019-06-26 EP disclosed
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2016-08-11 US disclosed
EP-3052495-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS Pfizer Inc. (US) 2016-08-10 EP disclosed
WO-2015049616-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER INC. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS BACE1, BACE2, PSEN2 L3MBTL1 4677/4885ALDH1A1 1923/4885TDP1 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.